BioNTech to Cut 90 More US Jobs Amid Strategic Realignment

BioNTech is eliminating 90 more jobs in the US—32 positions at its Gaithersburg, Maryland site and 58 roles at its Cambridge, Massachusetts location—as part of a broader 'strategic alignment' of its pipeline and US operations15.

These layoffs affect R&D and corporate roles and follow an earlier cut of 63 jobs in June at Gaithersburg, which was related to the discontinuation of BioNTech’s CAR-T cell therapy development for testicular cancer153.

The most recent pink slips at Gaithersburg are scheduled to take effect by September 16, 202515.

BioNTech cited aims of 'strategic alignment, operational efficiency and sustainable value creation' as the rationale for these workforce reductions while indicating continued investment in priority areas15.

Negotiations regarding further organizational changes are ongoing in Germany, and more information is expected later this year1.

Sources:

1. https://www.fiercebiotech.com/biotech/biontech-cuts-90-more-us-jobs-drugmaker-hones-pipeline-focus

3. https://www.fiercepharma.com/manufacturing/biontech-wind-down-cell-therapy-manufacturing-maryland-lay-63-it-ends-development-car

5. https://www.biospace.com/business/biontech-cuts-90-jobs-amid-strategic-alignment